CRYSTODIGIN Drug Patent Profile
✉ Email this page to a colleague
When do Crystodigin patents expire, and when can generic versions of Crystodigin launch?
Crystodigin is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in CRYSTODIGIN is digitoxin. There is one drug master file entry for this compound. Additional details are available on the digitoxin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CRYSTODIGIN?
- What are the global sales for CRYSTODIGIN?
- What is Average Wholesale Price for CRYSTODIGIN?
Summary for CRYSTODIGIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Patent Applications: | 7,359 |
| DailyMed Link: | CRYSTODIGIN at DailyMed |
US Patents and Regulatory Information for CRYSTODIGIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | CRYSTODIGIN | digitoxin | INJECTABLE;INJECTION | 084100-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
